Clinical Practice Guidelines Management of Dyslipidaemia 2023 (6th Ed.)
MESSAGE FROM THE DIRECTOR GENERAL OF HEALTH
Nearly 30 years since the publication of the first Malaysian Consensus on management of hyperlipidaemia, I am proud to
announce the publication of the 6th Clinical Practice Guidelines (CPG) on the management of dyslipidemia. Since the 5th CPG, published in 2017, there has been much development in both diagnosis and treatments of dyslipidemia. This CPG is timely, as
Malaysia has seen a rise in the prevalence of hypercholesterolemia in adults - a rise of 31.5% in 2011 to 38.1% in 2019.
Dyslipidemia remains one of the most deadly of the establishedcardiovascular risk factors. Compared to cigarette smoking, hypertension and diabetes, dyslipidemia is often only diagnosed when patients develop their first acute vascular event, such as a heart attack or stroke. Therefore, with the advent of such new therapeutics now available, with accompanying safety and efficacy clinical data, this CPG is timely to enable all healthcare professionals to optimise the management of their
patients with dyslipidemia.
This CPG comes with 13 new key messages and 19 key recommendations, valuable additions from the last CPG. The main aims of this 2023 CPG are to reduce the level of low-density lipoprotein (LDL-C), introduce new medications that can be used, in particularly for secondary preventions; and new updates in the Medical Nutrition therapy section. A significant reduction the LDL-C targets will see a corresponding reduction in serious cardiovascular outcomes. Improved point-of-care diagnostics will lead to more of the population to be diagnosed with dyslipidemia, and an aggressive, multi-aspect management plan being formulated, and administered, to each individual.
I would like to thank the Chairperson of the Writing Committee - Dr Jeyamalar Rajadurai - and her colleagues, and all those who contributed towards the publication of this CPG. I am certain that, with its dissemination, the burden of cardiovascular disease attributed to dyslipidemia, will be attenuated, and its deadly manifestations in the form of acute vascular events can be mitigated. For a condition so prevalent in Malaysia, this CPG will be a valuable resource from healthcare professionals practising at primary to tertiary care centres, and provide useful guidance to all stakeholders, so that this multidisciplinary approach will translate to improved health outcomes for both patients, and the population as a whole.
Dr Muhammad Radzi Abu Hassan
Director-General of Health Malaysia
Click the link below to download in PDF (15MB):
